Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 2NETWORK 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Gynecologic 2CNS 2Plasma cell 1Other solid neoplasm 1Myeloid 1Head & Neck 1Dermatologic 1

Conditions

Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 1

Interventions

Cisplatin 63Paclitaxel 56Carboplatin 38Taxes 24Radiotherapy 21Gemcitabine 16Brachytherapy 15Filgrastim 14Doxorubicin 13Topotecan 12Platinum 121,2-diaminocyclohexaneplatinum II citrate 12Docetaxel 11Radiation 7Granulocyte Colony-Stimulating Factor 7Chemotherapy, Adjuvant 7pegfilgrastim 6Surgical Procedures, Operative 6Radiotherapy, Intensity-Modulated 6Polymerase Chain Reaction 6Ifosfamide 6Etoposide 6Watchful Waiting 5Radiotherapy, Conformal 5Pemetrexed 5Gene Expression Profiling 5Fluorouracil 5Celecoxib 5Amifostine 5Observation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Fenretinide × Gynecologic × Clear all
NCT01535157 2020-08-27

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

South Plains Oncology Consortium

Phase 1/2 Terminated
12 enrolled
Gynecologic

Ovarian Neoplasms

NCT00017134 2013-06-10

Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

GOG Foundation

Phase NA Terminated
71 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡